What this trial studies
This study aims to explore the effects of short-term beetroot juice (BRJ) supplementation on cardiovascular health in post-menopausal women. The primary focus is to determine whether BRJ, rich in nitrates that increase nitric oxide (NO) bioavailability, can reduce blood pressure at rest and during exercise, as well as improve oxygen uptake during maximal exercise. Given the increased cardiovascular risk in post-menopausal women due to the loss of estrogen's protective effects, this research seeks to provide a novel, non-pharmacological intervention to enhance cardiovascular function during exercise in this population.
Conditions in scope
- Post-menopause
Interventions
- Beetroot juice (Dietary Supplement) — Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
- Beetroot juice placebo (Dietary Supplement) — Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
Who can join
Women only · Up to 65 Years
Inclusion criteria
- Females under the age of 65
- Self-reported absence of menstrual cycle for \>1 year
- BMI \<30 kg/m2.
- Able to walk on a treadmill and cycle on a stationary bike without problems.
- Proficient in Norwegian and able to provide informed consent.
Exclusion criteria
- Current or recent (last 5 years) regular smoker or user of nicotine products
- Addictions to alcohol or illegal drugs
- Allergy or intolerance (s) to nitrate or BRJ supplement.
- Diagnosed with cardiovascular disease (e.g., previous acute myocardial infarction or stroke, peripheral artery disease, heart failure), renal, or respiratory (e.g., asthma, sleep apnea).
- Regular usage of nitrate supplements, including beetroot juice
- Hormone replacement therapy.
- Uncontrolled high blood pressure (e.g., resting systolic and diastolic blood pressure \&gt;160/110 mmHg)
- Problems with very low blood pressure (e.g., severe dizziness upon standing)
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Bergen | Western Norway University of Applied Sciences | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: N/A
- Start date: 2025-09-09
- Primary completion: 2025-12-16
- Last update posted: 2026-03-10
- First posted: 2024-09-19
Sponsor & contact
Lead sponsor: Western Norway University of Applied Sciences (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Blood pressure (After 4 days of intervention)
- Blood pressure reactivity (After 4 days of intervention)
- Maximal oxygen consumption (After 4 days of intervention)
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT06598488 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.